Leukemia & Lymphoma
Volume 62, 2021 - Issue 11
Open access
2,422
Views
2
CrossRef citations to date
0
Altmetric
Original Articles
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies
Graham P. Collinsa NIHR Oxford Biomedical Research Center, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, UK
, Tracy N. Clevengerb Acerta Pharma, South San Francisco, CA, USA
, Kathleen A. Burkec Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA
, Buyue Yangb Acerta Pharma, South San Francisco, CA, USA
, Alex MacDonaldd Clinical Pharmacology & Safety Sciences, Oncology R&D, AstraZeneca, Cambridge, UK
, David Cunninghame Gastrointestinal and Lymphoma Unit, Royal Marsden and Institute of Cancer Research Biomedical Research Centre, London, UK
, Christopher P. Foxf Department of Clinical Haematology, Nottingham University Hospitals NHS Trust and Division of Cancer and Stem Cells, University of Nottingham, Nottingham, UK
, Andre Goyg Department of Medicine, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
, John Gribbenh Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
, Grzegorz S. Nowakowskii Division of Hematology, Mayo Clinic, Rochester, MN, USA
, Mark Roschewskij Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
https://orcid.org/0000-0003-0278-2635
Julie M. Vosek Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE, USA
, Anusha Vallurupallil Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA
, Jean Cheungb Acerta Pharma, South San Francisco, CA, USA
, Amelia Raymondc Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA
, Barrett Nuttallc Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA
, Dan Stetsonc Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA
, Brian A. Doughertyc Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA
, Stein Schalkwijkd Clinical Pharmacology & Safety Sciences, Oncology R&D, AstraZeneca, Cambridge, UK
, Larissa S. Carnevallim BioScience, Oncology R&D, AstraZeneca, Cambridge, UK
https://orcid.org/0000-0001-7432-0195
Brandon Willisn BioScience, Oncology R&D, AstraZeneca, Boston, MA, USA
, Lin Taoo Biometrics, Oncology R&D, AstraZeneca, South San Francisco, CA, USA
, Elizabeth A. Harringtonp Translational Science, Oncology R&D, AstraZeneca, Cambridge, UK
, Ahmed Hamdyb Acerta Pharma, South San Francisco, CA, USA
, Raquel Izumib Acerta Pharma, South San Francisco, CA, USA
, J. Elizabeth Peaseq Oncology Business Unit, AstraZeneca, Cambridge, UK
, Melanie M. Frigaultc Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA
& Ian Flinnr Sarah Cannon Center for Blood Cancer, Nashville, TN, USACorrespondence[email protected]
show all
Pages 2625-2636
|
Received 28 Oct 2020, Accepted 22 May 2021, Published online: 16 Jul 2021
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.